Aptevo Therapeutics (APVO) S-1/A IPO registration (amended)

Exhibit 107

Calculation of Filing Fee Tables

Form S-1

(Form Type)

Aptevo Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

	Security Type	Security Class Title(1)	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price(2)		Fee Rate		Amount of Registration Fee
Fees to Be Paid	Equity	Common stock, par value $0.001 per share(3)	Rule 457(o)			$	—	—		$	—
	Other	Pre-Funded Warrants to purchase common stock(3)(4)	Rule 457(g)				—	—			—
	Other	Series A Common Warrants to purchase common stock(4)	Rule 457(g)				—	—			—
	Other	Series B Common Warrants to purchase common stock(4)	Rule 457(g)				—	—			—
	Equity	Common Stock issuable upon exercise of the Series A Common Warrants	Rule 457(o)				—	—			—
	Equity	Common Stock issuable upon exercise of the Series B Common Warrants	Rule 457(o)				—	—			—
	Equity	Common Stock issuable upon exercise of the Pre-Funded Warrants(3)	Rule 457(o)				—	—			—
Fees Previously Paid	Equity	Common stock, par value $0.001 per share(3)	Rule 457(o)			$	12,000,000	0.00011020		$	1,322.40
	Other	Pre-Funded Warrants to purchase common stock(3)(4)	Rule 457(g)				—	—			—
	Other	Common Warrants to purchase common stock(4)	Rule 457(g)				—	—			—
	Equity	Common Stock issuable upon exercise of the Common Warrants	Rule 457(o)			$	12,000,000	0.00011020		$	1,322.40
	Equity	Common Stock issuable upon exercise of the Pre-Funded Warrants(3)	Rule 457(o)				—	—			—
Carry Forward Securities	—	—	—				—	—			—
Total Offering Amounts						$	15,000,000	0.00011020	$ 1,653.00
Total Fees Previously Paid									$ 2,644.80
Total Fee Offsets									—
Net Fee Due									$0

(1)	Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), there are also being registered such additional securities that may be issued because of events such as recapitalizations, stock dividends, stock splits and reverse stock splits, and similar transactions.
(2)	Estimated solely for the purpose of determining the amount of the registration fee in accordance with Rule 457(o) under the Securities Act.
(3)	The proposed maximum aggregate offering price of the shares of common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the shares of common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the shares of common stock and pre-funded warrants (including shares of common stock issuable upon exercise of the Pre-Funded Warrants), if any, is $5,000,000.
(4)	No fee due pursuant to Rule 457(g) under the Securities Act because the warrants are being registered in the same registration statement as the common stock issuable upon exercise of the warrants.